AstraZeneca's Oral GLP-1 Candidate Signals Shift Toward Daily Pills but Phase 2 Data Leave Key Questions on Durability and Equity Unanswered

The SOLSTICE phase 2b randomized controlled trial (n=406 adults with type 2 diabetes across nine countries) demonstrated that elecoglipron achieved HbA1c targets in nearly 90% of participants versus 25% on placebo and produced mean 10.5% weight loss at 26 weeks. As an industry-funded RCT, the study carries clear conflicts of interest and remains early-stage; no peer-reviewed publication has yet appeared in a high-impact journal. While the Healthline coverage correctly notes competition from Rybelsus and the newly approved oral Wegovy, it underplays adherence advantages of once-daily tablets over weekly injectables and overlooks emerging real-world evidence that oral formulations improve persistence by 15-20% in observational cohorts of similar size. Related phase 3 programs from Novo Nordisk and Eli Lilly suggest that next-generation oral agents may match injectable efficacy on glycemic control yet still lag on cardiovascular outcomes documented in the SELECT trial (n>17,000). Long-term safety signals, including potential muscle loss and gastrointestinal tolerability beyond 26 weeks, remain untested. For the millions managing diabetes or obesity, an oral option could expand access within 12-18 months if phase 3 succeeds, but pricing, insurance coverage, and equitable distribution in low-resource settings are absent from current reporting.